

IDS
f.led
2.11/05

DT01 Rec'd PCT/PTC 11 FEB 2005
Sheet 1 of 1 (2/11/05)

Form PTO-1449	ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO. 10/524520
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	APPLICANT LOIBNER, Hans et al.	
	FILING DATE February 11, 2005	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
/BD/	WO	0069460	A	2000-11-23	WIPO				

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

	Nakashio et al. "Peritoneal Dissemination is Inhibited by Treatment With Antibodies Against CD44H, Betal, Integrin, and Carcinostatic ..." International Journal of Oncology, Vol. 10, No. 2, 1997, pp. 355-362
	Schneider-Gaeddicke et al. "Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours" European Journal of Cancer, Vol. 31A, No 7-8, 1995, pp. 1326-1330
	Reithmueller et al., "Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial" Journal of Clinical Oncology, Vol. 16, No. 5, May 1998, pp. 1788-1794

EXAMINER /Brad Duffy/	DATE CONSIDERED 7/23/2007
--------------------------	------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IDS
filed
8/22/05

Form PTO-1449				ATTY. DOCKET NO. 4518-0108PUS1		APPLICATION NO. 10/524,520	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				APPLICANT LOIBNER, Hans et al.			
				FILING DATE February 11, 2005		GROUP	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/BD/	US 2001/0006618	A1	2001-07-05	Goldenberg			
/BD/	US 4,643,971		1987-02-17	Frader et al.			
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
/BD/	WO	01/23005	A1	2001-04-05	WIPO				
	WO	00/69460	A1	2000-11-23	WIPO				
	WO	01/03738	A1	2001-01-18	WIPO				
	WO	93/21940	A1	1993-11-11	WIPO				
	EP	1140168	B1	2002-06-26	EPO				

OTHER DOCUMENTS	
(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)	
	(Abstract) Swayne L.C. et al. " SPECT anti-CEA monoclonal antibody detection of occult colorectal carcinoma metastases" Journal Article, Vol. 16, No. 11, November 1991, pp.849-852
	(Abstract) Edington M.D. " Radioimmunoimaging of metastatic medullary carcinoma of the thyroid gland using an indium -111 labeled monoclonal antibody to CEA" Journal Article, Vol. 104, No. 6, December 1998, pp. 1004-1010
	(Abstract) Cote R.J. et al. " Intraoperative monoclonal antibody CC49" Journal Article, Vol. 77, No. 4, February 15, 1996, pp.613-620
	(Abstract) Lechner P. et al. " Tc-99m-labeled anti-CEA antibodies in intraoperative diagnosis of colorectal cancer" Journal Article, Vol. 34, No. 1, February 1995, pp.8-14

EXAMINER /Brad Duffy/	DATE CONSIDERED 7/23/2007
--------------------------	------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		APPLICANT LOIBNER, Hans et al.	
		FILING DATE February 11, 2005	GROUP
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	J.P. Chippaux and M. Goyffon. "Venoms, Antivenoms and Immunotherapy" Journal Toxicon, Vol.36, No. 6, May 7, 1997, pp. 823-846		
	G. Riethmüller. et.al. "Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial" Journal of Clinical Oncology, Vol.16, No.5, May 1998, pp.1788-1794		
	Tatsuaki, Nakashio et al. " Peritoneal dissemination is inhibited by treatment with antibodies against CD44H, B1 integrin, carcinostatic agents in NUGC-4 human gastric cancer cells" International Journal of Oncology, Vol. 10, 1997, pp.355-362		
	Barchi, Joseph J. Jr. " Emerging Roles of Carbohydrates and Glycomimetics in Anticancer Drug Design" Current Pharmaceutical Design, Vol. 6, 2000, pp.485-501		
	Ben-Yedidia Tamar and Arnon Ruth. " Design of Peptide and Polypeptide vaccines" Biotechnology, Vol.8, 1997, pp.442-448		
	Casadevall, Arturo and Scharff, Matthew D. " Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases" Clinical Infectious Diseases, Vol.21, 1995, pp.150-161		
	Glennie, Martin J. and Johnson, Peter W.M. " Clinical trials of antibody therapy" Journal Immunology Today, Vol.21, no. 8, August 2000, pp.403-410		
	Gollogly, V. Castronovo. " A possible role for the alpha 1-3 galactosyl epitope and natural anti-gal antibody in ontogenesis" Neoplasma Journal, Vol.43, No.5, 1996, pp.285- 289		
	Herlyn, Dorothy and Birebent Brigitte. " Advances in cancer vaccine development" the Finnish Medical Society Duodecim Vol.31, 1999, pp.66-78		
	Lewis, Jonathan J. and Houghton, Alan N. " Definition of tumor antigens suitable for vaccine construction" Cancer Biology, Vol.6, 1995, pp.321-327		
	Melief, Cornelis J.M. et al. " Peptide-based cancer vaccines" Current Opinion in Immunology, Vol.8, 1996, pp.651-657		
	Miyake, Masayuki. et. al. " Correlation of Expression of H/Ley/Leb Antigens with Survival in Patients with Carcinoma of the Lung" The New England Journal of Medicine, July 2, 1992, pp.14-18		
	Orntoft, F. Torber and Vestergaard, Else Marie. " Clinical aspects of altered glycosylation of glycoproteins in cancer" Electrophoresis Journal, Vol.20, 1999, pp.362-371		
	Scott, Andrew M. and Welt, Sydney. "Antibody-based immunological therapies" Journal of Current Opinion on Immunology, Vol. 9. 1997, pp.717-722		
	Weitz, Jurgen MD and Herfarath, Christian MD. " Surgical Strategies and Minimal Residual Disease Detection" Seminars in Surgical Oncology, Vol.20, 2001, pp.329-333.		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			